LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 1.14 USD -1.72% Market Closed
Market Cap: 30m USD

Gross Margin
LAVA Therapeutics NV

97.9%
Current
29%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
97.9%
=
Gross Profit
7.2m
/
Revenue
7.3m

Gross Margin Across Competitors

LAVA Therapeutics NV
Glance View

Market Cap
30m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.02 USD
Undervaluation 44%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
97.9%
=
Gross Profit
7.2m
/
Revenue
7.3m
What is the Gross Margin of LAVA Therapeutics NV?

Based on LAVA Therapeutics NV's most recent financial statements, the company has Gross Margin of 97.9%.

Back to Top